Insider Trading Alert - P, ILMN, ALXN, IBKR And RNR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 5, 2014, 146 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.84 to $26,546,700.00.

Highlighted Stocks Traded by Insiders:

Pandora Media (P) - FREE Research Report

Kavner Robert M who is Director at Pandora Media sold 10,000 shares at $35.51 on Feb. 5, 2014. Following this transaction, the Director owned 200,847 shares meaning that the stake was reduced by 4.74% with the 10,000-share transaction.

The shares most recently traded at $32.07, down $3.44, or 10.72% since the insider transaction. Historical insider transactions for Pandora Media go as follows:

  • 4-Week # shares sold: 4,400
  • 12-Week # shares sold: 13,200
  • 24-Week # shares sold: 343,614

The average volume for Pandora Media has been 8.8 million shares per day over the past 30 days. Pandora Media has a market cap of $7.0 billion and is part of the services sector and media industry. Shares are up 34.7% year-to-date as of the close of trading on Wednesday.

Pandora Media, Inc. provides Internet radio services in the United States. The company allows listeners to create up to 100 personalized stations to access unlimited hours of free music and comedy, as well as offers Pandora One, a paid subscription service to listeners. Currently there are 11 analysts that rate Pandora Media a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on P - FREE

TheStreet Quant Ratings rates Pandora Media as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full Pandora Media Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Illumina (ILMN) - FREE Research Report

Rastetter William H who is Director at Illumina sold 8,551 shares at $151.93 on Feb. 5, 2014. Following this transaction, the Director owned 4,464 shares meaning that the stake was reduced by 65.7% with the 8,551-share transaction.

The shares most recently traded at $150.87, down $1.06, or 0.7% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 4,333
  • 12-Week # shares sold: 9,333
  • 24-Week # shares sold: 40,960

The average volume for Illumina has been 1.6 million shares per day over the past 30 days. Illumina has a market cap of $19.2 billion and is part of the health care sector and drugs industry. Shares are up 37.07% year-to-date as of the close of trading on Wednesday.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 84.2. Currently there are 8 analysts that rate Illumina a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Illumina Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Link Max who is Director at Alexion Pharmaceuticals sold 40,000 shares at $155.16 on Feb. 5, 2014. Following this transaction, the Director owned 58,574 shares meaning that the stake was reduced by 40.58% with the 40,000-share transaction.

Bell Leonard who is Ceo at Alexion Pharmaceuticals sold 11,790 shares at $154.50 on Feb. 5, 2014. Following this transaction, the Ceo owned 963,276 shares meaning that the stake was reduced by 1.21% with the 11,790-share transaction.

Sinha Vikas who is Evp & Cfo at Alexion Pharmaceuticals sold 3,552 shares at $154.47 on Feb. 5, 2014. Following this transaction, the Evp & Cfo owned 129,775 shares meaning that the stake was reduced by 2.66% with the 3,552-share transaction.

Carmichael Clare who is SVP, Chief HR Officer at Alexion Pharmaceuticals sold 760 shares at $153.63 on Feb. 5, 2014. Following this transaction, the SVP, Chief HR Officer owned 8,703 shares meaning that the stake was reduced by 8.03% with the 760-share transaction.

Hallal David who is EVP, Chief Commercial Officer at Alexion Pharmaceuticals sold 3,119 shares at $154.45 on Feb. 5, 2014. Following this transaction, the EVP, Chief Commercial Officer owned 105,830 shares meaning that the stake was reduced by 2.86% with the 3,119-share transaction.

The shares most recently traded at $155.45, up $1.00, or 0.64% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares sold: 5,501
  • 12-Week # shares sold: 5,501
  • 24-Week # shares sold: 43,388

The average volume for Alexion Pharmaceuticals has been 1.2 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $30.6 billion and is part of the health care sector and drugs industry. Shares are up 17.55% year-to-date as of the close of trading on Wednesday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 50.7. Currently there are 17 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Nemser Earl H who is Vice Chairman at Interactive Brokers Group sold 15,475 shares at $20.89 on Feb. 5, 2014. Following this transaction, the Vice Chairman owned 83,738 shares meaning that the stake was reduced by 15.6% with the 15,475-share transaction.

Brody Paul Jonathan who is Chief Financial Officer at Interactive Brokers Group sold 8,604 shares at $20.89 on Feb. 5, 2014. Following this transaction, the Chief Financial Officer owned 46,555 shares meaning that the stake was reduced by 15.6% with the 8,604-share transaction.

Galik Milan who is SVP Software Development at Interactive Brokers Group sold 1,800 shares at $21.00 on Feb. 5, 2014. Following this transaction, the SVP Software Development owned 824,717 shares meaning that the stake was reduced by 0.22% with the 1,800-share transaction.

The shares most recently traded at $21.28, up $0.28, or 1.32% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 13,000
  • 12-Week # shares sold: 51,000
  • 24-Week # shares sold: 107,000

The average volume for Interactive Brokers Group has been 608,600 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.1 billion and is part of the financial sector and financial services industry. Shares are down 13.35% year-to-date as of the close of trading on Wednesday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.9%. The company has a P/E ratio of 24.5. Currently there are 3 analysts that rate Interactive Brokers Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

RenaissanceRe Holdings (RNR) - FREE Research Report

Todd Rider Fonner who is Svp & Cio at RenaissanceRe Holdings sold 2,000 shares at $90.00 on Feb. 5, 2014. Following this transaction, the Svp & Cio owned 56,844 shares meaning that the stake was reduced by 3.4% with the 2,000-share transaction.

The shares most recently traded at $90.52, up $0.52, or 0.57% since the insider transaction. Historical insider transactions for RenaissanceRe Holdings go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 67,000

The average volume for RenaissanceRe Holdings has been 625,400 shares per day over the past 30 days. RenaissanceRe Holdings has a market cap of $4.0 billion and is part of the financial sector and insurance industry. Shares are down 5.96% year-to-date as of the close of trading on Wednesday.

RenaissanceRe Holdings Ltd., together with its subsidiaries, provides reinsurance and insurance coverages and related services in the United States and internationally. The stock currently has a dividend yield of 1.24%. The company has a P/E ratio of 6.4. Currently there are 3 analysts that rate RenaissanceRe Holdings a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RNR - FREE

TheStreet Quant Ratings rates RenaissanceRe Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full RenaissanceRe Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?